CVS Health Corporation

CVS Health Corporation (CVS) (Q4FY23) – A wait and see approach makes sense

Highlights of the report

CVS Healthcare Corp’s $5bn Settlement in Opioid Litigation: Opioid Litigation: In 2023, CVS agreed to pay approximately $5bn to settle lawsuits related to its role in the opioid crisis. The lawsuits alleged that CVS failed to properly monitor and report suspicious orders of prescription opioids, contributing to the nation’s opioid epidemic.

CVS Health Corporation (CVS) Equity Report Q4FY23

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

CVS Health Corporation is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands

CVS’s revenue has increased by 12% to $93.81bn in Q4FY23 from $83.84bn in Q4FY22, Gross profit increased to $13.87bn in Q4FY23 from $13.85bn in Q4FY22 and the company’s gross margin has decreased to 15% in Q4FY23 from 17% in Q4FY22

Over the last 3 months CVS Health Corporation stock has generated return of 0.79%, the price of stock has increased to $75.08 on 15th March 2024 from $74.49 on 15th Dec 2023



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

CVS Health Corporation (CVS) (Q4FY23) – A wait and see approach makes sense



Company Reports

Sector Reports